These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Bacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria. Brown TL; Thomas T; Odgers J; Petrovski S; Spark MJ; Tucci J J Pharm Pharmacol; 2017 Mar; 69(3):244-253. PubMed ID: 28033675 [TBL] [Abstract][Full Text] [Related]
17. Respirable bacteriophages for the treatment of bacterial lung infections. Hoe S; Semler DD; Goudie AD; Lynch KH; Matinkhoo S; Finlay WH; Dennis JJ; Vehring R J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):317-35. PubMed ID: 23597003 [TBL] [Abstract][Full Text] [Related]
18. European regulatory conundrum of phage therapy. Verbeken G; De Vos D; Vaneechoutte M; Merabishvili M; Zizi M; Pirnay JP Future Microbiol; 2007 Oct; 2(5):485-91. PubMed ID: 17927471 [TBL] [Abstract][Full Text] [Related]
19. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. McCallin S; Alam Sarker S; Barretto C; Sultana S; Berger B; Huq S; Krause L; Bibiloni R; Schmitt B; Reuteler G; Brüssow H Virology; 2013 Sep; 443(2):187-96. PubMed ID: 23755967 [TBL] [Abstract][Full Text] [Related]
20. Re-establishing a place for phage therapy in western medicine. Kutter EM; Kuhl SJ; Abedon ST Future Microbiol; 2015; 10(5):685-8. PubMed ID: 26000644 [No Abstract] [Full Text] [Related] [Next] [New Search]